利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

16 条记录 (耗时 0.022 秒)

    Amido-phenyl-.alpha.-D-glucopyranoside derivatives
    11.
    发明授权
    Amido-phenyl-.alpha.-D-glucopyranoside derivatives 失效
    酰氨基 - 苯基-α-D-吡喃葡萄糖苷衍生物

    公开(公告)号：US4536572A

    公开(公告)日：1985-08-20

    申请号：US532676

    申请日：1983-11-02

    申请人： Wan S. Kim ,  Seo Y. Jeong ,  James C. McRea

    发明人： Wan S. Kim ,  Seo Y. Jeong ,  James C. McRea

    IPC分类号： A61K38/00 ,  C07H15/203 ,  C07H15/18

    CPC分类号： C07H15/203 ,  A61K38/00

    摘要： Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.

    摘要翻译： 对 - （琥珀酰氨基） - 苯基-α-D-吡喃葡萄糖苷和甘草吡喃糖苷，对 - （戊二酰氨基） - 苯基-α-D-吡喃葡萄糖苷和甘露糖吡喃糖苷和对 - （异硫代氰基苯基）-α- 葡萄糖和甘露糖苷与胰岛素反应形成相应的糖基化胰岛素，每个胰岛素分子含有1至3个糖基。 新型糖基化胰岛素抵抗聚集，显示抑制血糖水平的显着活性。

    Glycosylated insulin derivatives
    12.
    发明授权
    Glycosylated insulin derivatives 失效
    糖基化胰岛素衍生物

    公开(公告)号：US4489063A

    公开(公告)日：1984-12-18

    申请号：US532681

    申请日：1984-02-06

    申请人： Wan S. Kim ,  Seo Y. Jeong ,  James C. McRea

    发明人： Wan S. Kim ,  Seo Y. Jeong ,  James C. McRea

    IPC分类号： A61K38/00 ,  C07H15/203 ,  A61K37/26

    CPC分类号： C07H15/203 ,  A61K38/00 ,  Y10S514/866

    摘要： Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)- phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.

    摘要翻译： 对 - （琥珀酰氨基） - 苯基-α-D-吡喃葡萄糖苷和甘草吡喃糖苷，对 - （戊二酰氨基） - 苯基-α-D-吡喃葡萄糖苷和甘露糖吡喃糖苷和对 - （异硫代氰基苯基）-α- 葡萄糖和甘露糖苷与胰岛素反应形成相应的糖基化胰岛素，每个胰岛素分子含有1至3个糖基。 新型糖基化胰岛素抵抗聚集，显示抑制血糖水平的显着活性。

    Cannula apparatus and system for heparin removal from blood
    14.
    发明授权
    Cannula apparatus and system for heparin removal from blood 失效
    用于从血液中去除肝素的插管装置和系统

    公开(公告)号：US5324253A

    公开(公告)日：1994-06-28

    申请号：US844240

    申请日：1992-03-02

    申请人： James C. McRea ,  Robert J. Todd

    发明人： James C. McRea ,  Robert J. Todd

    IPC分类号： A61M25/00 ,  A61M25/01

    CPC分类号： A61M25/0026 ,  A61M1/3659 ,  A61M1/3675 ,  A61M2025/0031 ,  A61M2025/0037 ,  A61M25/005

    摘要： A system for selective removal of certain components from plasma drawn from a patient comprises an extracorporeal blood circulation circuit and a cannula. The extracorporeal blood circulation circuit has an uptake line for transporting blood from the patient, a plasma separator, and a return line connected to the plasma separator for transporting selectively depleted blood from the plasma separator to the patient. The plasma separator is connected to the uptake line for receiving the blood, selectively removing plasma components (e.g., heparin) by separating plasma from whole blood and interfacing such plasma with an adsorption substrate, recombining depleted plasma, and reinfusing selectively depleted blood into the return line for transport to the patient. The cannula has an uptake conduit with an intake end and an exit end, and a return conduit, connected to the uptake conduit, with an outflow end and an entry end. The exit end is connected to the uptake line of the bypass circuit and the entry end is connected to the return line of the bypass circuit. Structure at the outflow end of the return conduit alters the direction of flow and directs selectively depleted blood being returned to the patient into the right atrium of the patient's heart when the intake end of the uptake conduit is disposed within the patient's inferior vena cava. An alternative cannula with washers may be inserted into a venous return cannula whereby recirculation and pooling of the selectively depleted blood is prevented.

    摘要翻译： 从患者抽取的血浆中选择性地去除某些组分的系统包括体外血液循环回路和套管。 体外血液循环回路具有用于输送来自患者的血液的吸收线，血浆分离器和连接到血浆分离器的返回管线，用于将选择性排出的血液从血浆分离器输送到患者。 等离子体分离器连接到吸收管线用于接收血液，通过从全血中分离血浆并将这种血浆与吸附底物相接合，选择性地除去血浆成分（例如肝素），将耗竭的血浆重新结合并将选择性耗尽的血液重新输入回流 线路运送到病人。 套管具有吸入端和出口端的吸入导管和连接到吸收管道的返回管道，其具有流出端和入口端。 出口端连接到旁路电路的吸收线，入口端连接到旁路回路的返回线。 当吸入导管的进气端设置在患者的下腔静脉内时，返回管道的流出端处的结构改变流动的方向并且将选择性地耗尽的血液返回到病人的右心房。 具有垫圈的替代插管可以插入到静脉回流插管中，从而防止了选择性耗尽的血液的再循环和汇集。

    Glycosylated insulin derivatives
    16.
    发明授权
    Glycosylated insulin derivatives 失效
    糖基化胰岛素衍生物

    公开(公告)号：US4478830A

    公开(公告)日：1984-10-23

    申请号：US532917

    申请日：1984-02-06

    申请人： Wan S. Kim ,  Seo Y. Jeong ,  James C. McRea

    发明人： Wan S. Kim ,  Seo Y. Jeong ,  James C. McRea

    IPC分类号： A61K38/00 ,  C07H15/203 ,  A61K37/26

    CPC分类号： C07H15/203 ,  A61K38/00 ,  Y10S514/866

    摘要： Synthesized succinyl and glutaryl glucosamines, p-(succinylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides, p-(glutarylamido)-phenyl-.alpha.-D-gluco- and mannopyranosides and p-(isothiocyanotophenyl)-.alpha.-D-gluco- and mannopyranosides are reacted with insulin to form corresponding glycosylated insulins containing from 1 to 3 glycosyl groups per insulin molecule. The novel glycosylated insulins resist aggregation and show significant activity in depressing blood sugar levels.

    摘要翻译： 对 - （琥珀酰氨基） - 苯基-α-D-吡喃葡萄糖苷和甘草吡喃糖苷，对 - （戊二酰氨基） - 苯基-α-D-吡喃葡萄糖苷和甘露糖吡喃糖苷和对 - （异硫代氰基苯基）-α- 葡萄糖和甘露糖苷与胰岛素反应形成相应的糖基化胰岛素，每个胰岛素分子含有1至3个糖基。 新型糖基化胰岛素抵抗聚集，显示抑制血糖水平的显着活性。